NeoGenomics, Inc. (NASDAQ:NEO) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Monday.

Several other analysts also recently weighed in on NEO. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday, July 29th. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald set a $11.00 price target on NeoGenomics and gave the company a “buy” rating in a research note on Saturday, May 27th. Finally, BTIG Research reiterated a “buy” rating and set a $11.00 price target on shares of NeoGenomics in a research note on Sunday, May 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $10.40.

Shares of NeoGenomics (NASDAQ:NEO) traded up 1.30% on Monday, reaching $9.37. The company’s stock had a trading volume of 195,860 shares. The stock’s market cap is $742.45 million. The firm has a 50 day moving average price of $8.89 and a 200-day moving average price of $8.16. NeoGenomics has a 12-month low of $6.90 and a 12-month high of $9.93.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.03. The business had revenue of $66.09 million for the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a positive return on equity of 6.02% and a negative net margin of 2.81%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.04 EPS. Equities research analysts expect that NeoGenomics will post $0.18 EPS for the current year.

TRADEMARK VIOLATION WARNING: “NeoGenomics, Inc. (NEO) Upgraded at ValuEngine” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/07/neogenomics-inc-neo-upgraded-at-valuengine.html.

In other news, VP Jennifer Balliet sold 3,334 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $7.50, for a total value of $25,005.00. Following the sale, the vice president now owns 10,049 shares in the company, valued at $75,367.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alison L. Hannah bought 20,000 shares of the stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of $9.19 per share, for a total transaction of $183,800.00. Following the purchase, the director now directly owns 38,782 shares of the company’s stock, valued at $356,406.58. The disclosure for this purchase can be found here. Insiders sold 84,890 shares of company stock worth $665,707 in the last 90 days. Company insiders own 12.20% of the company’s stock.

Hedge funds have recently modified their holdings of the company. State Street Corp increased its stake in shares of NeoGenomics by 4.2% in the fourth quarter. State Street Corp now owns 915,073 shares of the medical research company’s stock worth $7,842,000 after buying an additional 36,540 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of NeoGenomics during the fourth quarter worth approximately $1,271,000. Teachers Advisors LLC increased its stake in shares of NeoGenomics by 0.4% in the fourth quarter. Teachers Advisors LLC now owns 93,314 shares of the medical research company’s stock worth $800,000 after buying an additional 396 shares during the last quarter. Cutler Group LP increased its stake in shares of NeoGenomics by 15.9% in the first quarter. Cutler Group LP now owns 13,087 shares of the medical research company’s stock worth $103,000 after buying an additional 1,800 shares during the last quarter. Finally, Mesirow Financial Investment Management Equity Management increased its stake in shares of NeoGenomics by 55.8% in the first quarter. Mesirow Financial Investment Management Equity Management now owns 50,190 shares of the medical research company’s stock worth $396,000 after buying an additional 17,975 shares during the last quarter. Hedge funds and other institutional investors own 78.31% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.